Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Phosphorus or phosphorus compound
Reexamination Certificate
2006-04-18
2006-04-18
Pak, John (Department: 1616)
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Phosphorus or phosphorus compound
C424S600000, C424S617000, C424S630000, C424S635000, C424S638000, C424S639000, C424S641000, C424S643000, C424S655000, C424S656000, C424S657000, C424S658000, C424S659000, C424S660000, C424S675000, C424S678000, C424S682000, C424S683000, C424S684000, C424S686000, C424S687000, C424S688000, C424S689000, C424S692000, C424S693000, C424S694000, C424S695000, C424S696000, C424S697000, C424S724000, C514S062000, C514S063000, C514S064000, C514S167000, C514S168000, C514S354000, C514S456000, C514S457000, C514S458000, C514S
Reexamination Certificate
active
07029703
ABSTRACT:
A dietary supplement for benefitting human bone health includes a calcium source, a source of vitamin D activity, and an osteoblast stimulant. A preferred calcium source is microcrystalline hydroxyapatite, which also contains protein (mostly collagen), phosphorus, fat, and other minerals. A preferred source of vitamin D activity is cholecalciferol, and a preferred osteoblast stimulant is ipriflavone. In addition to these basic ingredients, the composition can further include various other minerals known to occur in bone, vitamin C, and glucosamine sulfate, all of which exert beneficial effects on growth and maintenance of healthy bone. A method for benefitting human bone health involves administering a daily regimen of the dietary supplement.
REFERENCES:
Medline abstract, accession No. 2001449820 (2001).
Medline abstract, accession No. 2001608214 (2001).
Medline abstract, accession No. 92236913 (1992).
Promt Abstract, accession No. 1988:470186 (Aug. 1998).
Promt Abstract, accession No. 1999:105772 (Feb. 22, 1999).
Hendler, Sheldon S. The Complete Guide to Anti-Aging Nutrients. Simon and Schuster, NY, 1985, pp. 293-300.
Cranney, A., et al., “Responsiveness of Endpoints in Osteoporosis Clinical Trials—An Update,”The Journal of Rheumatologyvol. 26(1), pp. 222-228 Jan. 1999.
Chemical Abstracts 122:45482n., 1995.
PINNA-CAL. Product description [online] Twinlab, Date unavailable [retrieved from Internet on May 13, 2002] URL: http://shop.store.yahoo.com/twinlabproducts/0026.html.
Calcium Complex. Product description [online]. Natural Ways to Health, date unavailable, Retrieved from Internet on May 13, 2002] URL: http://WWW.NATURALWAYS.COM/Calcium.htm.
Nutritional Supplements Cal Apatite Plus™ Product description [online] Arthritis Center of Riverside, date unavailable [Retrieved from Internet on May 13, 2002. URL: http://WWW.THE ARTHRITISCENTER.COM/CAPLUS.HTM.
PINNA-CAL. World Mark [Retrieved on line from Internet on May 17, 2002 URL:http://tess.USPTO.gov/bin/showfield? f=doc&state=d9eer0.2.1. Jul. 1999.
I.R. Reid, et al.,Prophylaxis Against Vitamin D Deficiency in the Elderly by Regular Sunlight Exposure, vol. 15, Age and Ageing, 35-40, 1986.
D. Agnusdei, et al.,Metabolic and Clinical Effects of Ipriflavone in Established Post-Menopausal Osteoporosis, vol. 15, No. 2, Drug Exptl. Clin. Res, 97-104, 1989.
A. Pines, et al.,Clinical trail of microcrystalline hydroxyapatite compound(‘Ossopan’)in the prevention of osteoporosis due to corticosteroid therapy, vol. 8, No. 10, Current Medical Research and Opinion, 734-742, 1984.
Jan. J. Stepan, et al.,Quantitation of Growth Factors in Ossein-Mineral-Compound, vol. 49, Life Sciences, PL-79—PL-84, 1991.
M. Annefeld, et al.,The influence of ossein-hydroxyapatite compound(‘Ossopan’)on the healing of a bone defect, vol. 10, Current Medical Research Opinion, 241-250, 1986.
Lisa G. Abbott, et al.,Clinical Manifestations of Magnesium Deficiency, vol. 19, Miner Electrolyte Metab, 314-322, 1993.
D. R. Fraser,Vitamin D, vol. 345, The Lancet, 104-107, Jan. 14, 1995.
Marcel E. Ooms, et al.,Prevention of Bone Loss by Vitamin D Supplementation in Elderly Women: A Randomized Double-Blind Trial, vol. 80, No. 4, Journal of Clinical Endocrinology and Metabolism, 1052-58, 1995.
G.B. Melis, et al.,Lack of any estrogenic effect of ipriflavone in postmenopausal women, vol. 15, Journal of Endocrinology Invest, 755-761, 1992.
T. Ushiroyama, et al.,Efficacy of ipriflavone and 1 α vitamin D therapy for the cessation of vertebral bone loss, vol. 48, International Journal of Gynecology & Obstetrics, 283-88, 1995.
Attila B. Kovács,Efficacy of ipriflavone in the prevention and treatment of postmenopausal osteoporosis, vol. 41, Agents Actions, 86-87, 1994.
M. Valente, et al.,Effects of 1-Year Treatment with Ipriflavone on Bone in Postmenopausal Women with Low Bone Mass, vol. 54, Calcified Tissue International, 377-380, 1994.
Owen Epstein, et al.,Vitamin D hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary biliary cirrhosis, vol. 36, The American Journal of Clinical Nutrition, 426-30, Sep. 1982.
P. Rüegsegger, et al.,Comparison of the Treatment Effects of Ossein-Hydroxyapatite Compound and Calcium Carbonate in Osteoporotic Females, vol. 5, Osteoporosis International, 30-34, 1995.
D. Agnusdei, et al.,Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis, vol. 19, Bone and Mineral, S43-48, 1992.
D. Agnusdei, et al.,Efficacy of Ipriflavone in Established Osteoporosis and Long-Term Safety, vol. 61, Calcified Tissue International, S23-27, 1997.
Paul D. Saltman, et al.,The Role of Trace Minerals in Osteoporosis, vol. 12, No. 4, Journal of the American College of Nutrition, 384-89, 1993.
S. Adami, et al.,Ipriflavone Prevents Radial Bone Loss in Postmenopausal Women with Low Bone Mass over 2 years, vol. 7, Osteoporosis International, 119-125, 1997.
Jean-Yves L. Reginster,Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis, vol. 23, Bone and Mineral, 223-232, 1993.
Johnson Holly A.
Krumhar Kim C.
McDermott Will & Emery LLP
Metagenics, Inc.
Pak John
LandOfFree
Composition for promoting healthy bone structure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for promoting healthy bone structure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for promoting healthy bone structure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3570234